Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted
Thesis Summary

Science Applications International Corp (SAIC) is executing a critical strategic pivot away from low-margin, commoditized enterprise IT contracts toward higher-value mission and engineering services. Under the leadership of CEO Toni Townes-Whitley, the company has demonstrated strong operational execution, delivering a record 11.6% adjusted EBITDA margin in Q1 FY27. However, organic revenue growth remains highly constrained (0.5% in Q1 FY27) due to significant recompete headwinds, including the transition of the State Department's Vanguard contract to the multi-award EVOLVE vehicle. While SAIC's robust free cash flow generation (guided at >$600 million for FY27) and aggressive capital return program provide a solid floor, the stock is currently fairly valued relative to its growth profile, warranting a Hold recommendation until organic growth accelerates.

Sign in / Sign up to read more
This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.
Street view · analyst 12-month targets10 analysts · as of 18 Aug 2026
Low · most bearish analyst$93.00
Mean target$120.00
High · most bullish analyst$137.00
Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026
Scenarios · 12-month scenario targetsAnchored at research date
Bear CaseDownside scenario

Severe recompete losses under the EVOLVE vehicle and slower-than-expected federal procurement cycles lead to organic revenue contraction of more than 2%. Margin pressure intensifies due to unsustainable civilian margins and execution challenges during the portfolio realignment, causing free cash flow to fall below the $600 million target.

Base CaseCentral scenario

SAIC successfully navigates its portfolio transition, stabilizing organic revenue growth at 1-2% while sustaining adjusted EBITDA margins in the 10.1% to 10.3% range. The company successfully defends its footprint under the new EVOLVE contract vehicle and continues to deploy its strong free cash flow toward share repurchases and debt paydown, maintaining net leverage near 3.0x.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits
  • Strong operational execution and margin expansion, highlighted by a record 11.6% adjusted EBITDA margin in Q1 FY27.
  • Robust and highly visible cash flow generation, with FY27 free cash flow guided at greater than $600 million (equivalent to ~$14 per share).
  • Disciplined capital allocation focused on shareholder returns, including a consistent quarterly dividend of $0.37 per share and active share repurchases.
Sign in / Sign up to read more
Key Investment Risks
  • Significant recompete headwinds, particularly the transition of the $250 million run-rate Vanguard contract to the multi-award EVOLVE vehicle.
  • Low organic revenue growth (0.5% in Q1 FY27) reflecting a cautious federal spending environment and selective bidding strategy.
  • Execution risks associated with the ongoing portfolio realignment away from commoditized enterprise IT services.
Sign in / Sign up to read more
Thesis Invalidation Triggers
  1. Failure to win key task orders under the EVOLVE contract vehicle, leading to a material drop in the DHS or State Department business.
  2. Adjusted EBITDA margins falling below 10.0% on a sustained basis due to pricing pressures or cost overruns.
  3. Free cash flow generation dropping below $550 million, limiting the company's capacity for share repurchases and deleveraging.
Sign in / Sign up to read more

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Explore this dossier

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.